

ForPatients

by Roche

CNS Tumors Brain Tumor Solid Tumors Cancer

Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Trial Status

Active, not recruiting

Trial Runs In

8 Countries

Trial Identifier

NCT02650401 CO40778
RXDX-101-03

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

Hoffmann-La Roche

Sponsor

Phase 1

Phase

NCT02650401 CO40778 RXDX-101-03

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=0 Years & <= 18 Years

Healthy Volunteers

No